Drug intelligence / Profile preview

Metavac

Development stage: Preclinical
Lead developer: Vaxxel
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

Metavac is a live-attenuated vaccine candidate developed by Vaxxel for the prevention of respiratory infections caused by Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV). Administered intranasally, the vaccine is produced using a GMP-grade Vero cell line. It is designed to provide dual protection against two major causes of viral pneumonia and bronchiolitis, particularly in pediatric and elderly populations. As of 2024, the program is in preclinical development, with Phase I clinical trials anticipated to begin in the third quarter of 2025.

Brand names: Metavac
Other names: Metavac RSV-HMPV

Targets

hMPV (Human metapneumovirus)

Beyond the preview

Go deeper on Metavac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metavac.

Explore the full profile